Bioavailability of salbutamol
We read with interest the paper of Hindle and Chrystyn (May 1994; 49:549-53) in which the lung bioavailability of salbutamol (Ventolin, Allen & Hanburys, Uxbridge, UK) was augmented by 53-4% by using a Nebuhaler (Astra Pharmaceuticals, Kings Langley, UK) as assessed by 30 minute urinary excretion of salbutamol in normal volunteers. In this respect, measuring the plasma concentration of salbutamol, peak levels occur within five minutes of inhalation, in keeping with rapid lung absorption, and it is this which will therefore largely determine systemic 132-mediated effects of inhaled salbutamol. ' 
